Zydus Cadila has received final approval from the United States Food and Drug Administration (USFDA) to market Clobetasol Propionate Ointment USP, 0.05 percent.
At 12:42 hrs Cadila Healthcare was quoting at Rs 493.95, up Rs 2.55, or 0.52 percent.
The share touched its 52-week high Rs 558.00 and 52-week low Rs 342.00 on 12 June, 2017 and 26 December, 2016, respectively.
Currently, it is trading 11.48 percent below its 52-week high and 44.43 percent above its 52-week low.
Market capitalisation stands at Rs 50,567.77 crore.
Source : BSE
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
